U3-1784 (anti-FGFR4)

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab177857-100μg	100μg	现货
Ab177857-1mg	1mg	现货
Ab177857-5mg	5mg	现货
Ab177857-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: FGFR4

Accession#:P22455 (5) FGFR4 (5) Gene ID:2264 (5)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	U3-1784 (anti-FGFR4)
别名	CD 334 antibody \| CD334 antibody \| CD334 antigen antibody \| fc13h 10 antibody \| fc13h10 antibody \| Fgfr 4 antibody \| FGFR-4 antibody \| Fgfr4 antibody \| FGFR4_HUMAN antibody \| Fibroblast growth factor receptor 4 antibody \| Hydroxyaryl protein kinase antibo
英文别名	EC 2.7.10.1 \| FGFR-4
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	FGFR4
种属反应性	人(Human)
偶联	Unconjugated

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	lambda
SDS-PAGE	27.7 kDa (Light Chain) & 50.5 kDa (Heavy Chain), under reducing conditions; 186.9 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
分子类型	抗体

关联靶点（人）

FGFR4 Tclin 成纤维细胞生长因子受体 4(Fibroblast growth factor receptor 4) (0 活性数据)

点击查看靶蛋白信息： FGFR4

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

FGFR4 Tclin Fibroblast growth factor receptor 4 (3668 活性数据)

点击查看靶蛋白信息： FGFR4

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

FGFR4 Tclin FGFR4-KLB (0 活性数据)

点击查看靶蛋白信息： FGFR4

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: U3-1784 (anti-FGFR4) (Ab177857)

U3-1784 (anti-FGFR4) (Ab177857) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling FGFR4 (red) with U3-1784 (anti-FGFR4) (Ab177857). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Flow Cytometry: U3-1784 (anti-FGFR4) (Ab177857)

U3-1784 (anti-FGFR4) (Ab177857) - Flow Cytometry
Flow Cytometry analysis of HepG2 cells labelling FGFR4 (red) with U3-1784 (anti-FGFR4) (Ab177857). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

SEC: U3-1784 (anti-FGFR4) (Ab177857)

U3-1784 (anti-FGFR4) (Ab177857) - SEC
The purity of U3-1784 (anti-FGFR4) (Ab177857) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到4个结果

批号(Lot Number)	证书类型	货号
ZJ23F1202213	分析证书	Ab177857
ZJ23F1202214	分析证书	Ab177857
ZJ24F1113259	分析证书	Ab177857
ZJ24F1113257	分析证书	Ab177857

技术文档和文章

成纤维细胞生长因子家族（FGF）

Categories: 技术文章

探索主题:

成纤维细胞生长因子家族(FGF) FGF蛋白 FGF抗体细胞因子和生长因子 FGF抑制剂

引用文献

1. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA.. (1998) Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.. J Med Chem, 41 (5): (742-751). [PMID:9513602] [10.1021/jm970641d]
2. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al.. (2012) 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.. J Med Chem, 55 (1): (403-13). [PMID:22136433]
3. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M et al.. (2010) A structure-guided approach to creating covalent FGFR inhibitors.. Chem Biol, 17 (3): (285-95). [PMID:20338520]
4. Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA et al.. (2006) Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.. J Med Chem, 49 (4): (1475-85). [PMID:16480284]
5. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099]
6. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al.. (2013) Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.. ACS Med Chem Lett, 4 (1): (91-7). [PMID:24900568]
7. Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K et al.. (2011) A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.. Mol Cancer Ther, 10 (11): (2200-10). [PMID:21900693]
8. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238]
9. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese NA et al.. (2002) Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.. J Med Chem, 45 (17): (3772-93). [PMID:12166950]
10. Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S et al.. (2011) Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.. Bioorg Med Chem, 19 (21): (6274-84). [PMID:21967808]
11. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO et al.. (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 42 (26): (5369-89). [PMID:10639280]
12. Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N et al.. (2015) First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.. Cancer Discov, 5 (4): (424-37). [PMID:25776529]
13. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
14. Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J et al.. (2017) Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.. J Med Chem, 60 (15): (6516-6527). [PMID:28665128]
15. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898]
16. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y et al.. (2013) Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.. J Med Chem, 56 (3): (879-94). [PMID:23301703]
17. Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T et al.. (2014) Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.. Cancer Res, 74 (12): (3306-16). [PMID:24728076]
18. Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, Vagts A, Foster J, Liang J, Brush J, Gu Q et al.. (1999) FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4.. Cytokine, 11 (10): (729-35). [PMID:10525310]
19. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.. J Biol Chem, 282 (37): (26687-26695). [PMID:17623664]
20. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.. Bioorg Med Chem Lett, 14 (13): (3601-3605). [PMID:15177483] [10.1016/j.bmcl.2004.03.111]
21. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.. (2005) Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.. J Med Chem, 48 (12): (3991-4008). [PMID:15943473] [10.1021/jm0501275]
22. VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL.. (2005) Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.. J Med Chem, 48 (7): (2371-2387). [PMID:15801830] [10.1021/jm049355+]
23. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G.. (2006) Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.. Bioorg Med Chem Lett, 16 (2): (262-266). [PMID:16249085] [10.1016/j.bmcl.2005.10.015]
24. McDermott LA, Higgins B, Simcox M, Luk KC, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Liu JJ, Konzelmann F, Zhang Z, Flynn T, Morales O, Chen Y.. (2006) Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.. Bioorg Med Chem Lett, 16 (7): (1950-1953). [PMID:16460940] [10.1016/j.bmcl.2005.12.092]
25. Potashman MH, Bready J, Coxon A, DeMelfi TM, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H.. (2007) Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.. J Med Chem, 50 (18): (4351-4373). [PMID:17696416] [10.1021/jm070034i]
26. Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R.. (2015) Nintedanib: from discovery to the clinic.. J Med Chem, 58 (3): (1053-1063). [PMID:25474320] [10.1021/jm501562a]
27. Fan J, Dai Y, Shao J, Peng X, Wang C, Cao S, Zhao B, Ai J, Geng M, Duan W.. (2016) Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.. Bioorg Med Chem Lett, 26 (11): (2594-2599). [PMID:27117427] [10.1016/j.bmcl.2016.04.028]
28. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076]
29. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y.. (2018) Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.. J Med Chem, 61 (1): (140-157). [PMID:29189002] [10.1021/acs.jmedchem.7b01091]
30. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031]
31. Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA.. (2017) Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 27 (8): (1867-1873). [PMID:28279528] [10.1016/j.bmcl.2017.02.026]
32. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (1300-1325). [PMID:30195240] [10.1016/j.ejmech.2018.08.031]
33. Baska F, Sipos A, Őrfi Z, Nemes Z, Dobos J, Szántai-Kis C, Szabó E, Szénási G, Dézsi L, Hamar P, Cserepes MT, Tóvári J, Garamvölgyi R, Krekó M, Őrfi L.. (2019) Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.. Eur J Med Chem, 184 (111710-111710). [PMID:31614258] [10.1016/j.ejmech.2019.111710]
34. Lin X, Yosaatmadja Y, Kalyukina M, Middleditch MJ, Zhang Z, Lu X, Ding K, Patterson AV, Smaill JB, Squire CJ.. (2019) Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.. ACS Med Chem Lett, 10 (8): (1180-1186). [PMID:31413803] [10.1021/acsmedchemlett.9b00196]
35. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671] [10.1021/acs.jmedchem.7b01843]
36. Lu X, Chen H, Patterson AV, Smaill JB, Ding K.. (2019) Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.. J Med Chem, 62 (6): (2905-2915). [PMID:30403487] [10.1021/acs.jmedchem.8b01531]
37. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178] [10.1016/j.ejmech.2018.12.015]
38. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE.. (2020) Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.. ACS Med Chem Lett, 11 (4): (558-565). [PMID:32292564] [10.1021/acsmedchemlett.0c00015]
39. Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M.. (2020) Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.. Bioorg Med Chem, 28 (10): (115453-115453). [PMID:32278710] [10.1016/j.bmc.2020.115453]
40. Jin Q,Zhang D,Gao M,Jiang C,Zhang J. (2021) Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.. Bioorg Med Chem, 29 (115862-115862). [PMID:33218898] [10.1016/j.bmc.2020.115862]
41. Rezende Miranda R,Fu Y,Chen X,Perino J,Cao P,Carpten J,Chen Y,Zhang C. (2020) Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.. J Med Chem, 63 (20): (11484-11497). [PMID:33030342] [10.1021/acs.jmedchem.0c00044]
42. Fairhurst RA,Knoepfel T,Buschmann N,Leblanc C,Mah R,Todorov M,Nimsgern P,Ripoche S,Niklaus M,Warin N,Luu VH,Madoerin M,Wirth J,Graus-Porta D,Weiss A,Kiffe M,Wartmann M,Kinyamu-Akunda J,Sterker D,Stamm C,Adler F,Buhles A,Schadt H,Couttet P,Blank J,Galuba I,Trappe J,Voshol J,Ostermann N,Zou C,Berghausen J,Del Rio Espinola A,Jahnke W,Furet P. (2020) Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.. J Med Chem, 63 (21.0): (12542-12573). [PMID:32930584] [10.1021/acs.jmedchem.0c01019]
43. Kuriwaki I,Kameda M,Iikubo K,Hisamichi H,Kawamoto Y,Kikuchi S,Moritomo H,Kondoh Y,Terasaka T,Amano Y,Tateishi Y,Echizen Y,Iwai Y,Noda A,Tomiyama H,Nakazawa T,Hirano M. (2021) Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.. Bioorg Med Chem, 33 (116019-116019). [PMID:33486159] [10.1016/j.bmc.2021.116019]
44. Liu H,Niu D,Tham Sjin RT,Dubrovskiy A,Zhu Z,McDonald JJ,Fahnoe K,Wang Z,Munson M,Scholte A,Barrague M,Fitzgerald M,Liu J,Kothe M,Sun F,Murtie J,Ge J,Rocnik J,Harvey D,Ospina B,Perron K,Zheng G,Shehu E,D'Agostino LA. (2020) Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma.. ACS Med Chem Lett, 11 (10): (1899-1904). [PMID:33062171] [10.1021/acsmedchemlett.9b00601]
45. Chen X,Liu Y,Zhang L,Chen D,Dong Z,Zhao C,Liu Z,Xia Q,Wu J,Chen Y,Zheng X,Cai Y. (2021) Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.. Eur J Med Chem, 214 (113219-113219). [PMID:33618175] [10.1016/j.ejmech.2021.113219]
46. Partanen, J J and 6 more authors.. (1991) FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern.. The EMBO journal, [PMID:1709094]
47. Partanen, J J, Mäkelä, T P TP, Alitalo, R R, Lehväslaiho, H H and Alitalo, K K.. (1990) Putative tyrosine kinases expressed in K-562 human leukemia cells.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2247464]
48. Vainikka, S S and 5 more authors.. (1994) Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1.. The Journal of biological chemistry, (15): [PMID:7518429]
49. Ron, D D and 8 more authors.. (1993) Fibroblast growth factor receptor 4 is a high affinity receptor for both acidic and basic fibroblast growth factor but not for keratinocyte growth factor.. The Journal of biological chemistry, (15): [PMID:7680645]
50. Kostrzewa, M M and Müller, U U.. (1998) Genomic structure and complete sequence of the human FGFR4 gene.. Mammalian genome : official journal of the International Mammalian Genome Society, [PMID:9457674]
51. Takaishi, S S and 5 more authors.. (2000) Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells.. Biochemical and biophysical research communications, (19): [PMID:10631118]
52. Ezzat, Shereen S, Zheng, Lei L, Zhu, Xian-Feng XF, Wu, Gillian E GE and Asa, Sylvia L SL.. (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.. The Journal of clinical investigation, [PMID:11781352]
53. Bange, Johannes J and 16 more authors.. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.. Cancer research, (1): [PMID:11830541]
54. Haugsten, Ellen Margrethe EM, Malecki, Jedrzej J, Bjørklund, Sunniva Maria Stordal SM, Olsnes, Sjur S and Wesche, Jørgen J.. (2008) Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis.. Molecular biology of the cell, [PMID:18480409]
55. Wang, Jianghua J, Yu, Wendong W, Cai, Yi Y, Ren, Chengxi C and Ittmann, Michael M MM.. (2008) Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.. Neoplasia (New York, N.Y.), [PMID:18670643]
56. Ma, Zhiyong Z and 12 more authors.. (2008) Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.. International journal of cancer, (1): [PMID:18756523]
57. Wu, Xinle X and 10 more authors.. (2010) FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.. The Journal of biological chemistry, (19): [PMID:20018895]
58. Xu, Wei W and 8 more authors.. (2010) FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.. European journal of cancer (Oxford, England : 1990), [PMID:20638838]
59. Triantis, Vassilis V, Saeland, Eirikur E, Bijl, Nora N, Oude-Elferink, Ronald P RP and Jansen, Peter L M PL.. (2010) Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1.. Hepatology (Baltimore, Md.), [PMID:20683963]
60. Sugiyama, Nami N and 9 more authors.. (2010) FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex.. Proceedings of the National Academy of Sciences of the United States of America, (7): [PMID:20798051]
61. Sugiyama, Nami N and 12 more authors.. (2010) Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.. Cancer research, (15): [PMID:20876804]
62. Xu, Bin B and 6 more authors.. (2011) FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.. BMC cancer, (24): [PMID:21349172]
63. Frullanti, Elisa E and 9 more authors.. (2011) Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), [PMID:21412156]
64. Nakamura, Masao M and 7 more authors.. (2011) Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.. The Journal of biological chemistry, (29): [PMID:21653700]
65. Marshall, Amy D AD, van der Ent, Martijn A MA and Grosveld, Gerard C GC.. (2012) PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.. Molecular carcinogenesis, [PMID:21882254]
66. Ulaganathan, Vijay K VK, Sperl, Bianca B, Rapp, Ulf R UR and Ullrich, Axel A.. (2015) Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.. Nature, (24): [PMID:26675719]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

U3-1784 (anti-FGFR4)

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

相关产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器